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Abstract We present insights from a study on commu-
nicating Synthetic Biology conducted in 2008. Scientists
were invited to write press releases on their work; the
resulting texts were passed on to four journalists from
major Austrian newspapers and magazines. The journalists
in turn wrote articles that were used as stimulus material
for eight group discussions with select members of the
Austrian public. The results show that, from the lab via the
media to the general public, communication is character-
ized by two important tendencies: ﬁrst, communication
becomes increasingly focused on concrete applications of
Synthetic Biology; and second, biotechnology represents
an important benchmark against which Synthetic Biology
is being evaluated.
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Communicating Synthetic Biology in the public sphere
More than 10 years have passed since both the imports of
genetically manipulated crops and Dolly the Sheep led to
public and NGO protests in Europe. Since then, whenever a
new technology appears, the question arises whether the
new technology will be met with similar public reaction.
Synthetic Biology (SB) receives considerable attention
within expert circles, but the ﬁeld is not yet prominent in
the public domain. Media reporting has increased over the
past few years (Cserer and Seiringer, in preparation) but the
notion of ‘‘synthetic biology’’ has hardly entered public
awareness. Very ﬁrst studies on public perceptions of SB
indicate that most lay people in the US say they have heard
very little or nothing at all about SB [89% in the repre-
sentative study by Hart Research Associates (2008), and
82% in the online-survey by Kahan et al. (2009)]. We are
not aware of similar studies in other parts of the world.
The fact that there has been little discussion about SB up
to now does not mean, however, that it is uncontroversial.
The ﬁrst indication of an emerging public debate was an
open letter to the Second International Conference on
Synthetic Biology (SB 2.0) in May 2006, signed by 35
international NGOs, calling for inclusive public debate,
regulation and oversight of the rapidly advancing ﬁeld. The
scientiﬁc community has tried to address the concerns by
establishing self-imposed guidelines (Service 2006), with
reference to the approach chosen for genetic engineering in
the 1975 Asilomar declaration. In their analysis of the
SYNBIOSAFE e-conference on the societal aspects of SB,
Schmidt et al. (2008) highlight that within the SB com-
munity there is both a fear that public perceptions of SB
might reignite past debates on genetic engineering and a
hope that SB might be perceived as an emerging technol-
ogy similar to nanotechnology, which is a technology that
retained a comparatively more positive public image, at
least in Europe [Gaskell et al. 2006; for an international
comparison see Scheufele et al. (2008)].
The fact that the terminology and meaning of SB are
widely unknown and free from ‘‘stigma’’ in the public
domain (Kunreuther and Slovic 2001) makes SB an
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making processes. Research has shown that evaluations of
new phenomena are inﬂuenced by prior experiences with
phenomena deemed similar (Slovic 1987): experiences with
nuclear energy, with BSE or organic food, for example,
provided a basis for lay people’s evaluation of biotechnol-
ogy. Similarly, the public’s experiences with biotechnology
or nanotechnology may represent a basis for evaluating SB.
The concern here is with perceived similarities rather than
with similarity in a scientiﬁc sense. In novel, rapidly
changing contexts, people certainly do not need to know
scientiﬁc details but they do need to form opinions; the
‘pragmatic imperative’ of everyday life demands evaluation
even when important details are not known (Wagner and
Hayes 2005; Wagner 2007). That is, in contrast to scientiﬁc
observation, everyday life is not driven by epistemic goals
but rather is characterized by the desire to know whether or
not the novel requires further attention and action. There are
two major networks through which information about
technology-related events and evaluations ﬂow: the news
media and more informal personal networks, with different
‘‘ampliﬁcation stations’’—scientists, the media, groups of
the public—joining in at different points in the communi-
cation process (Kasperson et al. 1988). The metaphor of
ampliﬁcation highlights that information is not passed on in
an uninterested or unchanged way, but rather, individuals
and groups re-construct the issue at hand from their own
point of view. Thereby, both the hopes and the risks asso-
ciated with a technology are either ampliﬁed or attenuated,
depending on the perspective taken. Moving from the lab to
public views, the interpretation of technologies will tend to
be integrated into larger frames of values and the political
agenda of social and political groups.
In the following we provide ﬁrst insights on public views
of SB in Europe, where public resistance to biotechnology
hasbeenconsiderably stronger than inthe US (Gaskell et al.
2000). The research took place in Austria, a country with a
relatively skeptic stance on biotechnology from the outset
(Torgersen et al. 2001). Our analysis is based on a real-
world experiment conducted in 2008. Scientists working in
the ﬁeld of SB were invited to write press releases on their
work, which were passed onto Austrian journalists to be
turned into newspaper articles that ﬁnally were presented to
different groups ofthepublic. Inthe followingweask: What
makes scientiﬁc messages more or less likely to reach the
public audiences? And what role does prior experience with
biotechnology play in understanding and evaluating SB?
Method
In the following sections we describe the research design
used for investigating the transformation of information on
SB, as it was passed on from scientists to journalists and to
some groups of the public.
Luring Synthetic Biology out of the lab
In order to cover the ﬁeld of SB in a systematic way,
subﬁelds of SB were distinguished
1 and 15 scientists rep-
resenting these ﬁelds were invited to write a press release
on their recent work. Five scientists, covering the ﬁelds of
metabolic engineering, minimal organisms, and in silico
research, participated in the study. Furthermore, two
recently published press releases were included as this
material perfectly coincided with the timing and the pur-
pose of the study, and allowed for a more comprehensive
representation of SB. These latter texts were released by
the J. Craig Venter Institute (Scientists Create First Syn-
thetic Bacterial Genome)
2 and by the Institute for One-
World Health, Amyris Biotechnologies, and Sanoﬁ Aventis
(Agreement on the development of half-synthetic Artemis-
inin).
3 In total seven press releases covering the most
important developments in the ﬁeld were available for the
next step.
4
Making Synthetic Biology a newspaper headline
The second part of our research design consisted of
encouraging journalists to report on SB. Austrian science
and health journalists were identiﬁed with the help of a
journalists’ database. An invitation was sent to 28 jour-
nalists working for daily newspapers and magazines,
including high quality papers and tabloids, to write an
article in a way that was ready for press.
Four journalists afﬁliated with the Austrian newspapers
Der Standard, Salzburger Nachrichten, O ¨sterreich, and
News, agreed to participate in the study. While three of
these are daily newspapers, the latter is a weekly magazine.
The journalists received the seven press releases as input
for their article on SB. Upon receipt of the articles, they
1 The classiﬁcation was based on Benner and Sismour (2005),
O’Malley et al. (2008), and Schmidt (2009), and conducted with kind
support from colleagues in the SYNBIOSAFE project (http://www.
synbiosafe.eu/).
2 http://www.jcvi.org/cms/research/projects/synthetic-bacterial-genome/
press-release/.
3 http://www.sanoﬁ-aventis.de/live/de/medias/14315FF2-5B7B-4B8B-
9295-39DE4165E15D.pdf.
4 Today many universities have media relations departments that edit
press releases before publication. We acknowledge that our data
consists both of edited and non-edited materials. It remains an open
question to what degree this has inﬂuenced our results. However, we
think that investigating reactions to non-edited releases produced by
scientists themselves allow for interesting insights, especially since
scientists will not always get reviewed before going public (e.g. when
being interviewed, or speaking on the radio or TV).
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of reporting on SB. Finally, they participated in a telephone
interview. The journalists were reimbursed for their par-
ticipation in the study.
In line with the style of the editorial houses, the weekly
magazine article contains considerably more words than
the daily newspaper reports; furthermore, the more a daily
newspaper is considered high quality press in Austria the
longer the article is (Standard: 705 words, Salzburger
Nachrichten: 353 words, O ¨sterreich: 286 words, News:
1,009 words).
Synthetic Biology meeting groups of the public
Finally, the newspaper articles were presented to eight
groups of the lay public in September/October 2008. In
order to ensure a realistic appearance, the articles were
completed with logos and headers from the newspapers for
which the journalists had supposedly produced the text.
For each group discussion 6–9 individuals were invited,
with a total of 49 Austrian lay persons participating in the
meetings. The criterion for group composition was maxi-
misation of perspectives (Strauss and Corbin 1990). This
means that selected groups were expected to be either
positive (e.g. based on economic or scientiﬁc interests) or
sceptical (e.g. based on religious or environmental
grounds) about the topic.
5 Furthermore, group composition
was based on the criteria of sex, age, level of education,
rural versus urban living area, and political views. For this
analysis we focus on commonalities shared by the groups
rather than on group differences, hence a more detailed
description of the groups is irrelevant here.
Upon arrival, participants were welcomed and intro-
duced to the topic of SB (beforehand, they were told that
the discussion would be on ‘‘new technologies’’). After
making free associations with the term, participants were
provided with copies of the four media articles. After a
reading period of 10–15 minutes, the researchers encour-
aged a discussion on SB within the group. Finally, partic-
ipants ﬁlled out a questionnaire, were debriefed and
received ﬁnancial compensation for travel and time
expenditure.
6 The discussions were tape-recorded and
transcribed verbatim. These transcripts, together with the
press releases and the media articles, represent the data
used for the analyses reported in the following sections.
Results
From lab to headline: application matters
In this section we ask what makes press releases more or
less interesting for journalists reporting on SB. As dis-
cussed above, seven press releases were given to four
journalists who in turn wrote a newspaper article on SB.
7
Two of the journalists indicated that they were familiar
with Synthetic Biology; two said they were not. Both the
press release headings and the news article headlines are
shown in Table 1.
The journalists were asked to rank order the press
releases according to their usefulness (1 = most useful,
7 = least useful). Do the press releases differ in the jour-
nalists’ evaluation? A Friedman test indicates that indeed
they do; the null hypothesis that there is no difference
between the press releases’ usefulness can be rejected
(v
2 = 16.71, df = 6, p\0.05). Table 1 presents the press
releases sorted by their mean rank. The journalists agree to
a considerable degree which press releases are useful; But
what features of the press releases make them more or less
useful?
A closer look at Table 1 reveals that an important
commonality of the press releases considered most useful
by the journalists is that they discuss speciﬁc applications
of SB (Artemisinin production, fuel production, detecting
explosives). Similarly, in the news headlines, none refer
explicitly to Synthetic Biology, but two of the four stress
(medical) applications. Within the texts, all four articles
discuss fuel production, three mention medical applica-
tions, and two the possibility of using SB for detecting
explosives. Undoubtedly, the applications of SB play a key
role in newspaper articles. In support of this ﬁnding, the
journalists explicitly stressed that application matters. ‘‘The
big question is: What are the beneﬁts of the research
result?’’, one journalist states. As such, press releases are
noteworthy only when they are both new and closely
related to the readers’ problems and concerns.
With the exception of the press release from the Venter
Institute, press releases considered most useful by the
journalists also tended to contain relatively little ‘‘gene’’
vocabulary (words like gene, genetic, genome, genotype,
DNA). Gene vocabulary can be considered an indicator of
scientiﬁc description. Three of the four journalists indi-
cated that besides the applicability of research ﬁndings,
clarity and comprehensibility of the press releases are
important criteria for selection. Good press releases are
5 The following groups were selected because they could be expected
to be partisan in some way: students of different disciplines; members
of NGOs: either thematically related to the life sciences like
Greenpeace or not thematically related like Amnesty International;
individuals working for an economic interest institution or in a
religious organisation.
6 The Greenpeace Group did not accept this allowance on the ground
of their strict anti-corruption policy.
7 All four journalists, in addition to the press releases, indicated
having looked for further information on the internet; three of the four
journalists made use of other newspaper articles and one journalist
indicated having read scientiﬁc journal articles.
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people’’, one journalist says, ‘‘this saves journalists painful
work of translation; translation, which also increases the
danger of errors … The topic needs to be interesting for a
broad readership, newspapers no longer can afford to
publish specialised knowledge for specialists’’. If scientiﬁc
terminology is being used, journalists want explanations
and background information.
The two features of press releases deemed useful, that is
application focus and relative frequency of gene talk (fre-
quency of gene words/total words), are not unrelated. The
press releases that focus on a speciﬁc application of SB
make use of less gene talk (M = 0.002, SD = 0.002,
N = 3) than those that do not focus on a speciﬁc appli-
cation (M = 0.034, SD = 0.010, N = 4; F = 28.27,
P\0.01). In this study, scientists who focus less on the
scientiﬁc details but on implications of their research are
more likely to be heard by the journalists.
One press release, namely the one released by the
J. Craig Venter Institute, seems to represent an exception to
what has been described so far: although the press release
does not focus on a speciﬁc application of SB and contains
a comparatively high proportion of gene vocabulary, it is
nevertheless considered useful by the journalists. This
press release, however, had been discussed extensively in
the media at the beginning of 2008, so that it is likely that
the journalists were already familiar with it. This press
release is also unique in that it is the only press release that
mentions the issues of (potential) risks and ethical aspects
(by stating that the work of the group is under constant
ethical review). No other press release mentions such
issues. In contrast, three of the four newspaper articles take
Table 1 Characteristics and reception of press releases
Mean
rank
a
Frequency gen*
words (total words)
Reference to application(s) Reference to risks
or moral aspects
Fuel Medicine Detection of explosives
Press releases
Agreement on the development of
half-synthetic Artemisinin
b
2.00 1 (1283) x X 0 0
Scientists a step closer to producing fuel
from bacteria
2.75 0 (414) X 0 0 0
Synthetic bacterial genome 2.75 54 (1587) x 0 0 4
First environmental applications of Synthetic
Biology
c
3.50 2 (453) 0 0 X 0
Bacterial genomes rules for the construction
of synthetic cells
4.25 34 (718) 0 0 0 0
Living in symbiosis: just together? 5.75 20 (595) 0 x 0 0
In silico cells the study evolution [sic] 7.00 7 (312) 0 0 0 0
Newspaper articles
Artiﬁcial life from the lab X 0 X 4
Artiﬁcial life from the bio-designer X X X 4
Improved weapons against malaria x X 0 0
Bacteria for medicine X X 0 4
Group discussions
Group 1 X X X 4
Group 2 X X X 4
Group 3 X X X 4
Group 4 X X X 4
Group 5 X X X 4
Group 6 X X 0 4
Group 7 X X X 4
Group 8 X X X 4
X Focus on speciﬁc application; x parenthetic mentioning of application
a Press releases ranked according to usefulness as rated by journalists (1 = best, 7 = worst)
b Subtitle: Striving for a better provision of malaria patients
c Subtitle: Bacteria that detect explosives buried in soil
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problems, but these issues are given relatively little space.
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Generally, the consideration of these issues does not go
beyond the appraisal that risks and ethical aspects of SB
need to be discussed.
Moving on from the media to the discussion groups,
Table 1 suggests that the journalists’ emphasis on appli-
cation matches the concerns of the groups. All groups
discussed all applications (fuel, medicine, detection of
explosives), with the exception of the explosives detection
not being discussed in the students’ group. Moving from
the lab to the public domain, SB is increasingly thought of
in terms of its speciﬁc applications. Furthermore, the issue
of risks and moral/ethical aspects were discussed in all
groups, even if mostly in very general and vague terms. For
the groups, SB is above all a new technology that promises
both new opportunities and problems. But how do group
discussants come to discuss risks and dangers when these
issues are virtually absent in the press releases and paren-
thetically mentioned in the newspaper articles? This
question is addressed in the next section.
Making sense of Synthetic Biology: old wine in new
bottles?
While for scientists the ways SB relates to biotechnology
might be irrelevant, it is important for the public. Anchoring
is the process of classifying, categorizing and naming the
new and unknown (Moscovici 2001). By seeing the unfa-
miliar in the light of a more familiar technology, the unfa-
miliar is linked to a multitude of references, taking a more
familiar and meaningful form. In everyday life, people need
not understand scientiﬁc details, but rather how to act with
regard to the unfamiliar. ‘‘What does the new technology
mean for us?’’, is the question. Hence, anchoring SB in
biotechnology might be a lay strategy to make sense of the
innovation. If SB is anchored in terms of biotechnology,
then former controversies on biotechnology will be relevant
for SB as well. In the following we investigate whether, and
in what ways, SB is linked to or contrasted with biotech-
nology in the scientiﬁc press releases, in the news articles,
and in the peer-to-peer discussions.
Table 2 shows both the frequencies of gene vocabulary
(such as gene, genome, genetic, DNA, etc.) and the fre-
quencies of biotech vocabulary (such as genetic engineer-
ing, genetic manipulation, genetic modiﬁcation,
biotechnology, cloning, Dolly) for all three types of com-
munication. Although the two types of vocabulary certainly
are related, in this context, contrasting them allows for
interesting insights. Thus, the gene vocabulary is consid-
ered as a proxy for scientiﬁc description and detail, while
the biotech vocabulary is understood as a proxy for the
degree of anchoring of SB in former debates on biotech-
nology. Proportions of gene versus biotech words within
each type of text highlights that along the communication
process the proportions change considerably. While in the
press releases the proportion of gene to biotech vocabulary
is 17 to 1, it is 2 to 1 in the media reporting, and reverses in
the group discussions to a proportion of 1 to 3. This means
that overall, the discussion moves away from the concrete
processes and ﬁndings of SB to a broader discussion that is
clearly anchored in a discussion of biotechnology. But
what does this mean? Is this good or bad news for SB? In
the following we take a more in-depth look at the different
stations in the communication process.
Scientists
The scientists writing the press releases clearly avoid
linking their work to biotechnology. Only once is SB
explicitly related to genetic engineering: ‘‘A major goal of
SB is to understand which pathways of the bacterial
metabolism are responsible for important functions, and
then genetically engineer organisms that can perform the
desired function more effectively’’. A few other references
address biotechnology as (unsuccessful) development of
the past, or include implicit references to biotechnology
(e.g. by naming laboratories, companies, or journal titles).
Media reporting
These tendencies are mirrored in news reporting. On
the one hand, there are references to past biotech
Table 2 Proportion of gen* words and biotech* words within the
press releases, media articles and group discussions
Gen* words Biotech* words
Press releases (N = 7)
Minimum/maximum 0/54 0/5
Mean 16.86 1.43
SD 20.56 2.15
Media articles (N = 4)
Minimum/maximum 1/14 1/5
Mean 4.75 3.00
SD 6.18 1.83
Group discussions (N = 8)
Minimum/maximum 4/19 15/86
Mean 10.13 32.00
SD 5.11 23.01
8 A media analysis on SB from 2004 onwards in Austrian, German
and Swiss print media shows that in most of the published news
articles, potential beneﬁts were mentioned, but only half or less of
them referred to potential risks and/or ethical aspects (Cserer and
Seiringer, in preparation).
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lary primarily stems from the fact that those ‘‘doing’’ SB
must be named: frequently they are called genetic engi-
neers or biotechnologists.
9 In contrast to the press releases,
there also are a few instances in the news articles relating
SB to biotechnology in terms of regulation, risks and eth-
ical issues: ‘‘Critics point out that there still are no laws and
regulations although Synthetic Biology goes far beyond
traditional genetic engineering procedures’’ or ‘‘The con-
troversies on nuclear energy and on genetically modiﬁed
plants and stem cells have shown how important an early
debate on safety issues and ethical aspects is’’.
Group discussions
In the group discussions, references to biotechnology and
genetic engineering are frequent and varied.
10 Having been
confronted with the notion of ‘‘synthetic biology’’ at the
beginning of the discussions, all of the groups reported
being unfamiliar with the topic. However, after having read
the newspaper articles, a number of respondents reported
feeling vaguely familiar with what SB is about. As such,
SB often is interpreted as either a part, or as a further
development of biotechnology. Part of the increase in
biotech vocabulary therefore is due to the fact that the
question of whether SB is biotechnology or not is ardently
debated.
11 Repeatedly, the groups concluded that SB is the
‘‘next step’’ or ‘‘logical continuation’’ of genetic engi-
neering. Furthermore, an increase in biotech vocabulary
represented a rapid move away from deﬁnitions of SB to a
broader evaluation of the development. SB is indeed per-
ceived to be very similar to biotechnology: it is seen as
raising comparable questions; to imply interfering with
nature, life and the eco-system; and consequently as posing
similar moral questions and risks (such as side effects
spiraling out of control or unpredictable long-term conse-
quences). Furthermore, SB is being associated with bio-
technology (and other technologies) in a more general way.
The groups emphasize that SB, like biotechnology, can be
used for good and bad; it is about comparable goals (e.g.
for medical, environmental or energy applications); it
might well be driven by potent companies investing big
money; and it is expected to be hard to control in terms of
(international) political decision-making and regulation. In
summary, the hopes and concerns about SB correspond
highly with the concerns voiced in different European
countries about biotechnology some years ago (Wagner
et al. 2001). Even the engineering aspect of SB, which was
expected to raise concerns (Schmidt 2006), meets relatively
little discussion among the public: with notions like
‘‘genetic engineering’’ or ‘‘biotechnology’’, and techniques
such as cloning, everyday people already feel acquainted
with the idea of an engineered approach to life. This does
not mean that the issue does not raise concerns; however, it
does not raise more or less concerns than biotechnology
has in the past and present.
In a nutshell, one might argue, science has arrived at a
stage, which catches up with public fantasies that came to
the fore in the context of biotechnology in the 1990s. Now
it is possible to do what the public imagined was already
possible years ago. As such, SB appears to be old wine in
new bottles.
12
At the end of the discussions, respondents were asked in
a questionnaire whether they think that SB will deteriorate,
have no effect, or improve our way of life over the next
years. Forty-four percent of our discussants say that they do
not know; 16% think that SB will deteriorate life; 10%
believe that it will have no effect; and 30% say that SB will
improve life. Many participants in our study feel insecure
about what to expect from the new technology. One might
conclude that in terms of public evaluation, the fate of SB
still is an open question. There are people who are sceptical
and who might mobilise to take action against SB. Other
groups feel conﬁdent that overall the innovation will turn
out to be beneﬁcial, while others still are hesitant to take
sides. This latter uncertainty may be surprising, that is, if
SB is indeed anchored in biotechnology. But SB, like
biotechnology, might not be a uniform development and
lead to a variety of applications. The history of biotech-
nology has shown that while GM food was met with high
levels of opposition, biotechnology in the medical domain
experienced much more support (Gaskell et al. 2006). The
9 Sometimes they are also called ‘‘bio-engineers’’, ‘‘bio-designers’’,
and the like.
10 It was made sure that the biotechnology aspect was not introduced
by the interviewer and only taken up if introduced by the group itself.
11 Most groups came to the understanding that while genetic
engineering means changing, SB implies creating or manufacturing
life from scratch. While some see this to be a critical and dangerous
development, others think that—as long as applied to bacteria (and
not to more developed beings such as animals or human beings)—
constructing what already exists in nature is not particularly
worrisome.
12 If SB so clearly is understood in terms of biotechnology, might it
not be the case that it is also compared to nanotechnology which, at
least in Europe, is typically evaluated in a more positive light? In our
data, nanotechnology was mentioned only in two groups, namely in
those groups with the most advanced understanding of SB: the
Greenpeace group and the student group. In the student group, one
participant mentioned nanotechnology at the beginning of the
discussion when speculating what SB might be about. In the
Greenpeace group, a participant recalled reading an article on
nanotechnology, highlighting the merging tendencies of engineering
and biology. Still, in both groups, the issue of nanotechnology was not
taken up by other members nor was it discussed further. Nanotech-
nology is therefore clearly not an anchor for making sense of SB.
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met with varying levels of support (Pidgeon et al. 2008).
Similarly, people might also await SB’s different applica-
tions, while remaining alert to its potential problems and
risks.
Conclusion
SB can be seen as an innovation that challenges the taken-
for-granted and that needs to be ‘symbolically coped with’
by social actors (Wagner et al. 2002). SB still seems to be
in the pre-coping phase, a phase characterized by low
levels of public knowledge and uncertainty on what to
think about the new technology. Different groups take up
aspects of the innovation and combine it with former
experiences and knowledge. Biotechnology represents an
important anchor for sense-making of SB in the public
domain. While in our study neither journalists nor group
discussants are sure about whether SB should be consid-
ered part of biotechnology or not, they agree that both
technologies pose similar questions, opportunities and
problems. It is therefore not surprising that SB is consid-
ered newsworthy by journalists only if it results in (or at
least promises) useful applications; as with biotechnology,
perceived usefulness might turn out to be crucial for the
development (Gaskell et al. 2001; see also Gaskell et al.
2004). In our ﬁeld experiment, the fact that SB deals with
the understanding and construction of life, in itself, is not
perceived as different enough from biotechnology to merit
special attention. Anchored in biotechnology, SB is not
met with much surprise—it seems to be generally inter-
preted as old wine in new bottles. Whether and to what
degree this result holds in other countries is an open
question, and further research is needed. However, if SB is
so clearly anchored in biotechnology in Austria, it is likely
that it will be so in other countries as well. Solely
depicting SB rhetorically as different from biotechnology,
hence will not be enough to ensure public support.
Everyday people, at least in our study, clearly link SB to
biotechnology and its history, and want important ques-
tions to be addressed: What are the claimed beneﬁts? And
what is done to deal with risks and moral problems? How
can SB be controlled?
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